Praxis Precision Medicines vs Protagonist Therapeutics
Praxis Precision Medicines (PRAX), health care, and Protagonist Therapeutics (PTGX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Praxis Precision Medicines is worth $8.5B on the stock market and Protagonist Therapeutics $8.1B: Praxis Precision Medicines is valued at 5% more. Over the past year Praxis Precision Medicines's share price has moved +68.5% and Protagonist Therapeutics's +47.9%.
Key facts
- Praxis Precision Medicines market value
- $8.5B
- Protagonist Therapeutics market value
- $8.1B
- Protagonist Therapeutics P/E
- 26.4
- Praxis Precision Medicines revenue
- $0FY to 2025-12-31
- Protagonist Therapeutics revenue
- $46MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Praxis Precision Medicines | Protagonist Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $8.5Bhigher | $8.1Blower |
| Revenue | $0lower | $46Mhigher |
| Earnings | -$303.3Mlower | -$130.1Mhigher |
| Employees | 168higher | 149lower |
| Total assets | $937.9Mhigher | $668.2Mlower |
| Valuation | ||
| P/E | — | 26.4 |
| P/S | — | 177 |
| P/B | 6.8lower | 7.5higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | -344% |
| Balance sheet | ||
| Net assets | $878.1Mhigher | $614.7Mlower |
| Total liabilities | $59.8Mhigher | $53.5Mlower |
| Total debt | — | — |
| Cash on hand | $357.3Mhigher | $128.4Mlower |
| Price change | ||
| Today | -1.68%lower | -0.13%higher |
| 1 year | +68.5%higher | +47.9%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Polen Capital team<0.1% / <0.1%
Praxis Precision Medicines only (1)
Protagonist Therapeutics only (2)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Praxis Precision Medicines / Protagonist Therapeutics). Who owns PRAX · Who owns PTGX
More on Praxis Precision Medicines
Further comparisons
Praxis Precision Medicines against its closest peers
Protagonist Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Praxis Precision Medicines or Protagonist Therapeutics?
By market value, Praxis Precision Medicines is the larger: $8.5B against $8.1B for Protagonist Therapeutics. By revenue in its latest fiscal year, Protagonist Therapeutics is the larger: $46M against $0 for Praxis Precision Medicines.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Praxis Precision Medicines and Protagonist Therapeutics?
In their latest 13F filings, Polen Capital team holds both.
Cite this page
Funkfolio, “Praxis Precision Medicines vs Protagonist Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/prax-vs-ptgx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.